TRIAL OF RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR

重组粒细胞集落刺激因子的试验

• 批准号: 6307842
• 负责人: ROBIN OHLS
• 金额: $ 2.24万
• 依托单位: UNIVERSITY OF NEW MEXICO
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6307842
• 关键词: bacterial disease; blood disorder chemotherapy; blood toxicology; clinical research; clinical trials; colony stimulating factor; granulocyte; human subject; human therapy evaluation; leukopenia; neutrophil; newborn human (0-6 weeks); placebos; pregnancy toxemia /hypertension; recombinant proteins

The object of this study is to administer recombinant G-CSF (versus placebo) to newborn infants with neutropenia associated with one of the four following diagnoses: early-onset sepsis: maternal hypertension; late-onset (acquired) sepsis; or necrotizing enterocolitis (NEC); and to assess the effect of such treatment on the following four outcome of variables: blood neutrophil concentration, neutrophil production and function, severity of illness, and duration of illness.

本研究的目的是给予重组G-CSF（与安慰剂相比）与以下四种诊断之一相关的中性粒细胞减少症新生儿：早发性脓毒症：母体高血压;晚发性（获得性）脓毒症;或坏死性小肠结肠炎（NEC）;并评估这种治疗对以下四个变量结果的影响：血液中性粒细胞浓度、中性粒细胞产生和功能、疾病严重程度和疾病持续时间。